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OBJECTIVES This survey sought to assess the frequency of the use of thrombolytic therapy, invasive
coronary procedures (ICP) (angiography, percutaneous transluminal coronary angioplasty and
coronary artery bypass grafting [CABG]), variables associated with their use, and their impact
on early (30-day) and long-term (3-year) mortality after acute myocardial infarction (AMI).
BACKGROUND Few data are available regarding the implementation in daily practice of the results of clinical
trials of treatments for AMI and their impact on early and long-term prognosis in unselected
patients after AMI.
METHODS A prospective community-based national survey was conducted during January–February
1994 in all 25 coronary care units operating in Israel.
RESULTS Among 999 consecutive patients with an AMI (72% men; mean age 63 6 12 years) acute
reperfusion therapy (ART) was used in 455 patients (46%; thrombolysis in 435 patients [44%]
and primary angioplasty in 20 [2%]). Its use was independently associated with anterior AMI
location and hospitals with on-site angioplasty facilities, whereas advancing age, prior
myocardial infarction (MI) and prior angioplasty or CABG were independently associated
with its lower use. The three-year mortality of patients treated with ART was lower than in
counterpart patients (22.0% vs. 31.4%, p 5 0.0008), mainly as the result of 30-day to 3-year
outcome (12.4% vs. 21.1%; hazard ratio 5 0.73, 95% confidence interval [CI] 0.52 to 1.03).
Independent predictors of long-term mortality were: age, heart failure on admission or during
the hospitalization, ventricular tachycardia or fibrillation and diabetes. The outcome of
patients not treated with ART differed according to the reason for the exclusion, where
patients with contraindications experienced the highest three-year (50%) mortality rate. After
ART, coronary angiography, angioplasty and CABG were performed in-hospital in 28%,
12% and 5% of patients, respectively. Their use was independently associated with recurrent
infarction or ischemia, on-site catheterization or CABG facilities, non–Q-wave AMI and
anterior infarct location. In the entire study population, and in patients with a non–Q-wave
AMI, performance of ICP was associated with lower 30-day mortality (odds ratio [OR] 5
0.53, 95% CI 0.25 to 0.98, and OR 5 0.21, 0.03 to 0.84, respectively), but not thereafter.
CONCLUSIONS This survey demonstrates the extent of implementation in daily practice of ART and ICP and
their impact on early and long-term prognosis in an unselected population after AMI. (J Am
Coll Cardiol 1999;34:70–82) © 1999 by the American College of Cardiology
Several large-scale randomized clinical trials in patients with
acute myocardial infarction (AMI) have demonstrated that
thrombolytic therapy reduces mortality early after AMI (1).
However, these studies failed to demonstrate an extra
benefit after hospital discharge (2). Other randomized
studies evaluating the physiologic effectiveness of thrombo-
lytic therapy demonstrated extended long-term mortality
benefit of early successful complete reperfusion (Thrombol-
ysis in Myocardial Infarction [TIMI] grade 3 flow) (3,4),
which may be related to improved left ventricular function
at the time of hospital discharge (3–5). Recently, several
moderate-sized randomized studies have reported that pri-
mary percutaneous transluminal coronary angioplasty with-
out antecedent thrombolytic therapy may improve prognosis
after AMI (6).
Although randomized trials are the preferred method for
assessing therapeutic modalities, useful information can also
be gained from prospective registry data which demonstrate
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to what extent therapeutic measures like acute reperfusion
therapy (ART) (thrombolysis or primary angioplasty) and
invasive coronary procedures (ICP) (angiography, nonpri-
mary angioplasty and coronary artery bypass grafting
[CABG]) were implemented in daily practice in unselected
AMI patients hospitalized in coronary care units (CCUs).
Such an assessment on a national basis has seldomly been
conducted (7–10).
The purpose of the present study was to determine the
clinical practice pattern of the use of thrombolysis, ICP and
medical management of unselected patients with AMI, in a
prospective, observational national survey conducted in all
CCUs in Israel, in 1994, and their impact on in-hospital
complications and short- (30-day) and long-term (three-
year) prognosis.
METHODS
Patient population. A nationwide prospective survey was
performed during a two-month period (January and Febru-
ary 1994) in all 25 CCUs operating in Israel, as described
elsewhere (11). In brief, demographic, historical and clinical
data including in-hospital complications, medical manage-
ment and procedures performed were collected on specific
forms for all participants by dedicated study physicians in
the CCUs. The diagnosis of AMI was based on clinical,
electrocardiographic and enzymatic findings. Eligibility for
inclusion in the survey was validated before discharge from
the CCU. Thrombolytic therapy was used at the discretion
of each center. Reasons for not utilizing thrombolytic
therapy were recorded. In patients with more than one
reason for exclusion from thrombolytic therapy, one reason
was selected after completion of the survey on the basis of
the following scale of priority: 1) contraindication to throm-
bolysis; 2) unqualifying electrocardiogram (ECG); 3) late
arrival; and 4) other reasons (i.e., advanced age, nonspecific
symptoms, death before decision was taken and spontane-
ous reperfusion). There were no uniform guidelines for the
use of coronary arteriography, angioplasty or CABG, but
most of the centers used a “conservative strategy” of “watch-
ful waiting” with coronary arteriography followed by coro-
nary mechanical reperfusion (12). On-site catheterization
and CABG facilities were available in 19 and 11 of the
centers, respectively.
Thirty-day and three-year mortality rates were assessed
for all patients participating in the survey from hospital
charts and by matching the identification numbers of the
patients with the Israeli National Population Register.
Statistical analysis. All analyses were performed using
SAS (Cary, North Carolina) statistical software. Chi-square
and t tests were used to determine the significance of the
differences between proportions and mean values, respec-
tively. Results of continuous variables are reported as
mean 6 1 SD. The nonparametric Wilcoxon test was used
to compare the time from pain onset to thrombolytic
therapy in the different groups. Two-sided p values are
reported.
Stepwise logistic regression analyses (SAS LOGISTIC
Procedure) were performed to assess potential variables
associated with the use of ART (thrombolysis or primary
angioplasty) and ICP (angiography, nonprimary angioplasty
and CABG) during the hospitalization period.
Survival curves were estimated by use of the Kaplan-
Meier method. The significance of the difference between
the survival curves was assessed by the log-rank test (SAS
LIFETEST Procedure).
Primary risk models were constructed to determine vari-
ables independently associated with mortality. Gender and
ART were added to the best model selected if they were not
significant, in order to determine their prognostic signifi-
cance. For 30-day mortality a stepwise logistic regression
analysis (SAS LOGISTIC Procedure) was used, and for
three-year mortality in 30-day survivors and cumulative
three-year mortality, Cox proportional-hazard regression
models (SAS PHREG Procedure) were used. In all stepwise
procedures, a variable was allowed to entered into the model
if it made a significant contribution at the 0.15 level, and
was removed if after subsequent addition of other variables,
it no longer made a contribution at the 0.10 level.
RESULTS
Patients’ Characteristics
During the survey period, 999 patients (721 men, 72%,
mean age 63.4 6 12.2 years) were hospitalized for AMI. Of
them 455 patients (46%) received ART (thrombolysis 435
patients [44%] and primary angioplasty 20 patients [2%])
and 544 patients did not. The baseline characteristics of
both groups are presented in Table 1.
Acute Reperfusion Therapy
Thrombolysis. Thrombolytic therapy was used in 435
patients. Streptokinase was the most common thrombolytic
agent used (85%); tissue-type plasminogen activator (tPA)
or other thrombolytic agents were used in 4% and 11%,
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ART 5 acute reperfusion therapy
CABG 5 coronary artery bypass grafting
CCU 5 coronary care unit
CI 5 confidence interval
ECG 5 electrocardiogram
HR 5 hazard ratio
ICP 5 invasive coronary procedures
MI 5 myocardial infarction
NQWMI 5 non–Q-wave myocardial infarction
OR 5 odds ratio
TIMI 5 Thrombolysis in Myocardial Infarction
tPA 5 tissue-type plasminogen activator
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respectively. In-hospital thrombolytic therapy was started in
the CCU setting in 79% of the cases, in the emergency
room in 16% and in other departments in 4%. In only 1.5%
of the cases prehospital thrombolytic therapy was initiated
in the mobile CCU setting. The median time from pain
onset to thrombolysis (reported for 83% of thrombolysed
patients [n 5 361]) was 2.5 h (mean 3.1 6 2.2 h). This time
distribution was ,1.5 h: 22% of the patients; 1.5 to 3 h:
46%; 3.5 to 6 h: 27%; and .6 h: 5% of the patients. This
time interval was slightly longer in women than in men
(median time 3.0 vs. 2.5 h, respectively, p 5 0.17), and with
advancing age (median time for age ,55 years: 2 h; 55 to 64
years: 2.5 h; 65 to 74 years: 3 h; and for age .75 years: 3 h;
p 5 0.14).
Primary angioplasty. Primary angioplasty was performed
in 20 patients (2%), in 10 of the 19 centers with catheter-
ization facilities; 12 cases were performed in three centers,
and the other eight cases in seven centers. The main reason
for performing primary angioplasty was contraindication to
thrombolysis (eight patients, 40%). The patients’ baseline
characteristics, including Killip class on admission (class I,
14 patients [70%]), were similar to those of patients who
underwent thrombolysis. None of these patients had a
subsequent angioplasty or CABG during the hospitalization
course.
During the survey period, 544 patients (54%; 52% of men
and 61% of women, p 5 0.008) were excluded from ART.
Of them, 474 patients (87%) had only one reason for
exclusion, and 70 patients (13%) had $2 reasons. The main
reason for exclusion from ART was unqualifying ECG (234
patients [23%]). Other reasons were: late arrival (129
patients [13%]), contraindication (114 patients [11%]) and
other reasons (67 patients [7%]). There was no difference in
the proportion of these reasons between men and women.
Variables Associated With Acute Reperfusion Therapy Use
The proportion of patients treated with ART declined
significantly with advancing age (age ,55 years: 54%; 55 to
64: 53%; 65 to 74: 39%, and $75 years old: 34%; p for trend
,0.0001; Table 2). Women were treated with ART less
frequently than men (39% vs. 48%, respectively, p 5 0.008).
However, the difference was of borderline statistical signif-
icance after multivariate adjustment (Table 2). Prior angio-
plasty or CABG were independently associated with lower
use of ART, whereas anterior infarct location and hospital-
ization in a center with on-site catheterization facilities were
associated with its increased use (Table 2).
Invasive Coronary Procedures
During the Index Hospitalization
Coronary angiography. After ART, subsequent in-
hospital coronary angiography (not including 20 patients
with primary angioplasty) was performed in 271/979 pa-
tients (28%). Of them 164 patients (61%) underwent
angioplasty or CABG during the index hospitalization
(Table 3). Coronary arteriography use was irrespective of
whether the patients received thrombolysis or not (Tables 2
and 3). Its use significantly declined with advancing age (age
,55 years: 38%; 55 to 64: 27%; 65 to 74: 25%, and $75
years old: 11%; p for trend ,0.0001; Table 2), and was
lower in women than in men (21% vs. 28%, respectively,
p , 0.0001). However, after multivariate adjustment the
lower use of coronary angiography in women was not of
statistical significance (Table 2). Recurrent myocardial in-
farction (MI) or recurrent ischemia, hospitalization in
centers with catheterization facilities, anterior infarct loca-
tion and non–Q-wave MI (NQWMI) were independently
associated with the use of coronary arteriography, whereas
Killip class $II on admission, a history of cerebrovascular
event and diabetes were associated with its lower use (Table 2).
Angioplasty. After ART, subsequent angioplasty (not in-
cluding 20 patients with primary angioplasty) was per-
formed in 118/979 patients (12%). It was performed more
frequently in patients initially treated with thrombolysis
(15% vs. 9%, p 5 0.004; Table 3). However, after adjust-
ment, performance of angioplasty during the index hospi-
talization was not associated with thrombolysis use (Table
Table 1. Baseline Characteristics of Patients Treated or Not
Treated by Acute Reperfusion (Thrombolysis or
Primary Angioplasty)
Acute Reperfusion
p
Value
Yes*
(n 5 455)
No
(n 5 544)
Age (yr) (mean 6 SD) 61.3 6 11.9 65.2 6 12.2 , 0.0001
Range (yr) 23–88 29–92
$65 yr 189 (42) 314 (58) , 0.0001
Male gender 347 (76) 374 (69) 0.008
History of
Angina 101 (22) 154 (28) 0.027
CHF 18 (4) 82 (17) , 0.0001
Prior MI 101 (22) 189 (35) , 0.0001
CABG/angioplasty 16 (4) 45 (8) 0.002
Diabetes 116 (25) 165 (30) 0.09
Hypertension 181 (40) 237 (44) 0.23
Hyperlipidemia 108 (24) 135 (25) 0.69
CVA 17 (4) 39 (7) 0.019
Family history 63 (14) 68 (13) 0.53
Smoking 187 (41) 180 (33) 0.009
MI location
Anterior 235 (52) 252 (46) , 0.0001
Inferior/posterior 205 (45) 213 (39)
Lateral 12 (3) 49 (9)
Undetermined 3 (1) 30 (6)
Q wave 359 (79) 284 (52) , 0.0001
Killip class $II on
admission
127 (28) 198 (36) 0.004
Peak CK (IU) 1,605 6 1,880 947 6 1,315 , 0.0001
*Thrombolysis in 435 patients, and primary angioplasty in 20.
CABG 5 coronary artery bypass grafting; CHF 5 congestive heart failure; CK 5
creatine kinase; CVA 5 cerebrovascular accident; MI 5 myocardial infarction.
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2). Other variables associated with the use of angioplasty are
presented in Table 2.
Coronary artery bypass grafting. The use of CABG dur-
ing the index hospitalization was low in this survey (46
patients, 5%). Its use was similar in patients treated with
ART and in their counterparts (Table 3). On-site CABG
operation facilities, recurrent MI or recurrent ischemia and
NQWMI were independently associated with increased use
of CABG operation (Table 2).
In-Hospital Medications
Patients treated with ART more frequently received hepa-
rin, aspirin and beta-adrenergic blocking agents, and less
frequently received diuretics and digitalis, as compared with
their counterparts (Table 3). The use of other medication
was similar in both groups.
In-Hospital Complications
Patients treated with ART more frequently experienced
ventricular tachycardia (all types) or fibrillation, bleeding
complications and recurrent infarction, and less frequently
experienced paroxysmal atrial flutter/fibrillation and conges-
tive heart failure than their counterparts (Table 3).
Mortality
The 30-day, 30-day to 3-year and 3-year cumulative mor-
tality rates for the patients who participated in the survey
were: 12.1%, 17.1% and 27.1%, respectively. Mortality
increased significantly with advancing age (Fig. 1, Table 4).
Women fared worse than men, with higher 30-day (23.7%
vs. 10.0%, p 5 0.009) and 30-day to 3-year crude mortality
rates (36.0% vs. 17.6%, p 5 0.015). However, after adjust-
ment, the odds ratio for death in women as compared with
men was of borderline significance at 30 days, but not
thereafter (Table 4). Other variables independently associ-
ated with increased mortality are presented in Table 4. Use
of ICP was associated with decreased 30-day mortality
(odds ratio [OR] 0.53), but not thereafter. Hospitalization
in centers with on-site catheterization facilities was not
associated with lower mortality.
The 30-day, 30-day to three-year and three-year crude
mortality rates were lower in patients treated with ART as
compared with counterpart patients, but reached statistical
significance only after 30 days (Table 3, Fig. 2). After
multivariate adjustment (Table 4), patients receiving ART
had a similar 30-day mortality as their counterparts (OR
0.96, 95% confidence interval [CI] 0.60 to 1.54), but a lower
mortality thereafter with a difference that amplified after 30
days through 3 years (hazard ratio [HR] 0.73, 95% CI 0.52
to 1.03).
The outcome of patients excluded from ART (i.e.,
contraindication, unqualifying ECG, late arrival and other
reasons) differed according to the reason for exclusion
(Table 5, Fig. 3). Patients excluded from ART (mainly
thrombolysis) because of contraindications (n 5 114) had
the highest 30-day (OR 1.78) and three-year mortality rates
(HR 1.71). In patients excluded from ART because of late
arrival (n 5 129) or other reasons (n 5 67), the 30-day and
the three-year mortality rates did not differ significantly
from patients treated with ART. On the other hand,
patients with an unqualifying ECG (n 5 234) had a lower
30-day mortality rate (OR 0.47), but an increased 30-day to
three-year mortality (HR 1.50) as compared with patients
who underwent ART. In this latter group, 153/234 patients
(65%) had a NQWMI.
Table 2. Variables Associated With the Use of Acute Reperfusion, Coronary Angiography, Angioplasty and CABG
Variables
Procedure
Acute Reperfusion*
(n 5 455),
OR (95% CI)
Angiography
(n 5 271),
OR (95% CI)
Angioplasty
(n 5 118),
OR (95% CI)
CABG
(n 5 46),
OR (95% CI)
Age (10-yr increments) 0.89 (0.72–0.91) 0.73 (0.63–0.84) 0.66 (0.55–0.79) 0.87 (0.67–1.12)
Female gender 0.77 (0.56–1.06) 0.89 (0.60–1.31) 1.30 (0.78–2.13) 0.60 (0.25–1.27)
Prior MI 0.64 (0.47–0.87) — — —
Prior angina — 1.67 (1.16–2.41) — —
Prior CABG or PTCA 0.47 (0.25–0.86) — — —
Killip class $II on admission — 0.39 (0.26–0.59) 0.26 (0.13–0.48) —
Prior CVA — 0.33 (0.12–0.78) — —
Anterior location 1.27 (0.98–1.65) 1.47 (1.07–2.04) 1.53 (1.01–2.31) —
Non–Q-wave MI † 1.96 (1.41–2.70) — 2.50 (1.35–4.76)
On-site hospital facilities 1.79 (1.34–2.40)‡ 2.45 (1.60–3.84)‡ 1.52 (0.94–2.55)‡ 3.61 (1.73–8.50)§
Diabetes — 0.70 (0.47–1.02) 0.63 (0.36–1.04) —
Recurrent MI/ischemia † 7.35 (4.73–11.59) 5.09 (3.11–8.29) 2.85 (1.38–5.61)
Acute reperfusion † — — —
*Thrombolysis or primary angioplasty. †Was not included in the analysis; — Did not enter into the model in the stepwise procedure. On-site hospital facilities were considered:
‡hospitals with catheterization facilities; §hospitals with CABG operation facilities (OR 5 1). Each column represents the ORs for variables selected as significant predictors
in the stepwise logistic analysis.
CI 5 confidence interval; OR 5 odds ratio. Other abbreviations as in Table 1.
73JACC Vol. 34, No. 1, 1999 Gottlieb et al.
July 1999:70–82 Long-Term Prognosis After AMI
Non–Q-Wave Infarction
A NQWMI was noted in 356 patients. The baseline
characteristics, management and in-hospital complications
of NQWMI patients treated with an early ICP (n 5 124) or
conservatively (n 5 232) are presented in Table 6. Patients
treated with ICP were younger, and had anterior infarct
location more often and a better Killip class on admission.
Other baseline characteristics of both groups were compa-
rable. The ICP group patients were treated with thrombol-
ysis, heparin, aspirin, nitrates and beta-blockers more often,
and with digitalis and diuretics less often. The ICP group
experienced recurrent AMI or ischemia more often (four-
fold) than their counterpart group. The prognosis of
NQWMI patients treated or not with ICP differed (Table
6, Fig. 4). The 30-day (1.6% vs. 9.9%, p 5 0.004), 30-day
to 3-year (15.6% vs. 23.9%, p 5 0.07) and cumulative
three-year crude mortality rates (16.9% vs. 31.5%, p 5
0.003) were lower in the former. However, after adjustment
for age, gender, history of diabetes, angina, prior MI,
anterior infarct location, congestive heart failure on admis-
sion (Killip class $II) or during the hospitalization course,
ventricular tachycardia or fibrillation, ART and hospitaliza-
tion in a center with on-site coronary catheterization facil-
ities, performance of early ICP in patients with NQWMI
was associated with lower 30-day mortality (OR 0.21, 95%
CI 0.03 to 0.84), but not thereafter from 30 days to 3 years
(HR 1.01, 95% CI 0.47 to 2.15). Hospitalization in a center
with on-site coronary catheterization facilities was not
associated with early (OR 0.98, 95% CI 0.37 to 2.94) or
long-term outcome (HR 1.01, 95% CI 0.47 to 2.15).
DISCUSSION
In the present survey, reflecting the clinical practice of the
medical community at large in an unselected AMI popula-
tion hospitalized in all CCUs operating in Israel, in 1994,
half of the patients received ART (mainly thrombolysis).
Acute reperfusion therapy was associated with decreased
three-year mortality (22.0% vs. 31.4%, p 5 0.0008), mainly
as the result of 30-day to three-year outcome (12.4% vs.
21.1%; HR 0.73). Patients excluded from ART because of
contraindication carried the worst prognosis (twofold risk as
compared with patients treated with ART). After ART,
subsequent use of ICP during the index hospitalization
course was relatively low (28%), reflecting the “conservative
strategy” of “watchful waiting” with coronary arteriography
(12). Variables independently associated with ICP use were
recurrent infarction or ischemia, on-site catheterization or
CABG facilities, NQWMI and anterior infarct location.
Performance of ICP was associated with lower 30-day
mortality in the entire study population (OR 0.53) and in
patients with a NQWMI (OR 0.21), but not thereafter.
Figure 1. Thirty-day and three-year crude mortality rates by age
subgroups (p for trend ,0.0001, for both 30-day mortality and
incremental three-year mortality rates).
Table 3. In-Hospital Invasive Coronary Procedures,
Medications, Complications and Mortality of Patients Treated
or Not Treated by Acute Reperfusion
Acute Reperfusion
p
Value
Yes
(n 5 455)
No
(n 5 544)
Invasive coronary
procedures
Angiography* 132 (30) 139 (26) 0.10
Angioplasty* 67 (15) 51 (9) 0.004
CABG 19 (4) 27 (5) 0.55
Medications
IV heparin 401 (88) 374 (69) , 0.0001
Aspirin 407 (90) 424 (78) , 0.0001
Nitrates 367 (81) 433 (80) 0.68
ACE-I 155 (34) 210 (39) 0.14
Beta-blockers 218 (48) 209 (38) 0.003
Calcium antagonists 95 (21) 124 (23) 0.47
Digitalis 38 (8) 64 (12) 0.08
Diuretics 119 (26) 194 (36) 0.001
Complications
VT/VF 82 (18) 47 (9) , 0.0001
II° III° AV Block 42 (9) 39 (7) 0.23
PAF 26 (6) 63 (12) 0.001
CHF 66 (15) 113 (21) 0.01
Cardiogenic shock 33 (7) 34 (6) 0.53
Bleeding 22 (5) 6 (1) 0.0004
Recurrent MI 23 (5) 6 (1) 0.001
Recurrent ischemia 45 (10) 53 (10) 0.94
Rupture/VSD 6 (1.3) 2 (0.6) 0.20
Stroke 5 (1.1) 3 (0.6) 0.33
Mortality
30-day 50/455 (11.0) 71/544 (13.1) 0.32
1-year cumulative 68/455 (15.0) 122/544 (22.4) 0.004
3-year cumulative 100/455 (22.0) 171/544 (31.4) 0.0008
30-day to 3-year 50/405 (12.4) 100/473 (21.1) 0.0006
*Out of 435 patients (not including 20 patients who underwent primary PTCA).
ACE-I 5 angiotensin-converting enzyme inhibitors; AV 5 atrioventricular; IV 5
intravenous; PAF 5 paroxysmal atrial flutter/fibrillation; VF 5 ventricular fibrilla-
tion; VT 5 ventricular tachycardia; VSD 5 ventricular septal defect. Other
abbreviations as in Table 1.
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Thrombolytic therapy. In this community-based nation-
wide survey 44% of patients received thrombolytic therapy
according to the discretion of each center. Similar rates of
thrombolysis use were reported from Canada (13) and New
Zealand (14). Higher rates were reported in Germany (52%)
(9), in the United Kingdom (72%) among patients with final
diagnosis of definite AMI (15) and in selected patients
eligible for participation in randomized trials, such as those
studied in the GISSI-3 (16) and the ISIS-4 (17) trials
('70%) carried out in Europe. A lower rate of thrombolysis
use (32%) was recently reported by the French AMI Survey
in 1995 (10) and from 11 countries in Europe, in 1993–
1994 (36%; ranging from 13% to 52%) (18). In the U.S. as
compared with Europe, lower figures (23% to 35%) have
been recorded (7,8,19–22).
In the current survey streptokinase was the most common
thrombolytic agent used (85%), similar to other places in
Europe (9,17,18) and dissimilar to the U.S. practice, where
the most common thrombolytic agent used is tPA ('70%)
(7,21). This practice relates to the lower cost of streptoki-
nase as compared with tPA, and the use of the latter in
selected cases where its benefit was proven, that is, non-
Figure 2. Three-year Kaplan-Meier cumulative survival curves for patients who underwent acute reperfusion and those who did not;
differences were assessed by log-rank test; p 5 0.0007.
Table 4. Multivariate Stepwise Logistic Regression Analyses to Predict 30-Day, 30-Day to
Three-Year and Three-Year Cumulative Mortality
Predictors
Mortality
30-Day,
OR* (95% CI)
30-Day to 3-Year,
HR† (95% CI)
3-Year Cumulative,
HR† (95% CI)
Age (10-yr increments) 1.69 (1.34–2.16) 1.83 (1.53–2.18) 1.73 (1.52–21.98)
Female gender 1.39 (0.88–2.20) 0.93 (0.66–1.31) 1.11 (0.86–1.643)
Diabetes 1.81 (1.15–2.84) 2.30 (1.65–3.19) 2.04 (1.60–2.61)
Q-wave MI 2.22 (1.33–3.81) — —
Killip $II on admission
or CHF during
hospitalization
6.96 (4.06–12.56) 2.06 (1.47–2.90) 2.98 (2.26–3.94)
VT/VF 3.03 (1.77–5.16) — 1.88 (1.37–2.57)
Invasive coronary
procedures‡
0.53 (0.27–0.98) — —
Acute reperfusion 0.96 (0.60–1.54) 0.73 (0.52–1.03) 0.87 (0.68–1.24)
*Variables included in the stepwise logistic regression analysis were: age, history of diabetes, angina, prior MI, anterior infarct
location, Q-wave infarction during the index hospitalization, congestive heart failure on admission (Killip class $II) or during
the hospitalization course, ventricular tachycardia or fibrillation, invasive coronary procedures during the hospitalization course
and hospitalization in a center with on-site coronary catheterization facilities. Acute reperfusion and gender were added to the
best model selected. †By Cox proportional-hazard regression model, including the same variables. ‡Performance of either
coronary angiography or angioplasty (not including primary angioplasty) or CABG during the hospitalization course. HR 5
hazard ratio. Other abbreviations as in Tables 1 to 3.
75JACC Vol. 34, No. 1, 1999 Gottlieb et al.
July 1999:70–82 Long-Term Prognosis After AMI
elderly patients presenting within 3 h from symptoms onset
with anterior AMI (23).
The median time from symptom onset to thrombolysis
was 2.5 h in this survey, slightly shorter than in other reports
(7,9,12). Elderly and female patients received thrombolytic
therapy later than their counterparts, similar to other reports
(7,12,24). Thrombolysis was initiated in most cases in the
hospital CCU (79%), in 16% in the emergency room and
prehospital (mobile CCU) in only 1.5%. This low prehos-
pital thrombolysis utilization rate is in accordance with
reports from Europe (2.5%) (18), and in discordance with
reports from the U.S. (7,21), and may be explained, in part,
by the fact that most urban places in Israel are located at a
reasonable distance from the nearby hospital and have a
mobile CCU service. Thus, because of the rapidity of
transportation, the direct transfer of many patients from the
mobile CCU to in-hospital CCU, and the preference of
cardiologists to initiate thrombolytic therapy in a hospital
CCU setting, in most of the cases thrombolytic therapy was
initiated in a hospital CCU.
Primary angioplasty. Primary angioplasty represents an
alternative method for myocardial reperfusion (6). However,
its use requires special facilities and a trained, experienced
team of medical personnel. Fewer than 20% of hospitals in
the U.S. and less than 10% of hospitals in Europe are able
to meet these requirements (25). A similar situation exists in
Israel, and despite the fact that 19 of the 25 CCUs have
on-site catheterization facilities, primary angioplasty was
rarely used (20 patients, 2%). A low rate of primary
angioplasty use was also noted in a survey in Germany
(1.4%) (9) and in the NRMI-1 (3.1%) (7) and NRMI-2
Figure 3. Three-year Kaplan-Meier cumulative survival curves for patients who underwent acute reperfusion and those who did not by
reason of exclusion (contraindication, unqualifying electrocardiogram [ECG], late arrival and other reasons).
Table 5. Crude and Adjusted Mortality Rates of Patients Treated or Not Treated by Acute Reperfusion by Reason for Exclusion
Group of Patients
Mortality
30-Day 30-Day to 3-Year 3-Year Cumulative
n (%) OR* (95% CI) n (%) HR* (95% CI) n (%) HR* (95% CI)
Acute reperfusion (n 5 455) 50 (11.0) 1.0 50 (12.4) 1.0 100 (22.0) 1.0
No acute reperfusion because of
Contraindication (n 5 114) 33 (28.9) 2.07 (1.14–3.37) 24 (29.6) 1.78 (1.09–2.92) 57 (50.0) 1.71 (1.23–2.38)
Unqualifying ECG (n 5 234) 12 (5.1) 0.47 (0.22–0.97) 48 (21.6) 1.50 (1.01–2.24) 60 (25.6) 0.96 (0.69–1.34)
Late arrival (n 5 129) 15 (11.7) 0.76 (0.36–1.53) 18 (15.8) 0.96 (0.56–1.66) 33 (25.6) 0.91 (0.61–1.35)
Other reasons (n 5 67) 11 (16.4) 1.14 (0.48–2.55) 10 (17.9) 1.11 (0.56–2.20) 21 (31.3) 1.16 (0.72–1.87)
†p value , 0.0001 0.12 , 0.0001
‡p value , 0.0001 0.001 , 0.0001
*The odds ratio (OR) or hazard ratio (HR) of not undergoing acute reperfusion (thrombolysis or primary angioplasty) because of contraindication, unqualifying electrocardiogram
(ECG), late arrival or other reasons as compared with patients who underwent acute reperfusion (reference group) by multivariate analyses adjusting for variables selected in Table
4. †p value for differences between crude mortality rates among the four groups of patients who did not undergo acute reperfusion. ‡p value for differences between crude mortality
rates among all groups.
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surveys (3.9%) (8) in the U.S., whereas a higher rate of use
was noted in the MITI Registry (8.5%) (21) and the French
AMI Survey (13%) (10).
Factors associated with the use of acute reperfusion. In
this survey, factors independently associated with the use of
ART were anterior infarct location and on-site catheteriza-
tion facilities. In patients with anterior infarction the risk of
developing large infarction is greater than in counterpart
AMI patients, hence there is a greater potential for myo-
cardial salvage by either thrombolysis or primary angio-
plasty. This concurs with previous studies showing the
greatest survival benefit with thrombolysis (1) or with
primary angioplasty (6) in high risk patients, that is, anterior
AMI. The independent association between use of ART
and hospitalization in centers with on-site catheterization
facilities (OR 1.75) indicates that in these centers as
compared with centers without such facilities, a more
aggressive reperfusion strategy with either thrombolysis
(47% vs. 34%, respectively, p , 0.001) or primary angio-
plasty (2.6% vs. 0.4%, respectively, p 5 0.03) is in use. This
finding is in accordance with the GISSI-3 trial (26) and in
discordance with the MITI Registry (20).
On the other hand, advanced age, prior infarction and
prior angioplasty or CABG were independently associated
with lower use of ART, whereas female gender had a
borderline association. The independent association be-
tween advanced age and lower use of ART (mainly throm-
bolysis) is in accordance with other studies (7,8,19,20,
26,27). The progressive rise in the incidence of major
hemorrhagic complications with increasing age formed the
Table 6. Baseline Characteristics, Management, Complications and Mortality of 356 Patients
with Non–Q-wave MI Treated or Not Treated by Invasive Coronary Procedures
Invasive Coronary Procedure*
p
Value
Yes
(n 5 124)
No
(n 5 232)
Age (yr) (mean 6 SD) 59.5 6 11.7 66.5 6 11.5 , 0.0001
$65 yr 47 (38) 142 (61) , 0.0001
Male gender 96 (77) 155 (67) 0.04
History of
Angina 40 (32) 69 (30) 0.62
Prior MI 37 (30) 90 (39) 0.08
CABG/angioplasty 8 (7) 27 (12) 0.12
Diabetes 25 (20) 62 (27) 0.17
Hypertension 51 (41) 104 (45) 0.50
Smoking 48 (39) 69 (30) 0.09
Anterior MI location 75 (60) 105 (45) 0.006
Killip class $II on admission 20 (16) 87 (38) , 0.0001
Peak CK (IU) 681 6 701 800 6 918 0.18
Management
Angioplasty 48 (39) — —
CABG 26 (21) — —
Thrombolysis 37 (30) 49 (21) 0.07
IV heparin 111 (90) 153 (66) , 0.0001
Aspirin 109 (88) 182 (78) 0.03
Nitrates 107 (86) 169 (73) 0.004
ACE-I 43 (35) 81 (35) 0.96
Beta-blockers 70 (57) 92 (40) 0.002
Calcium antagonists 31 (25) 69 (30) 0.34
Digitalis 4 (3) 22 (10) 0.03
Diuretics 23 (19) 79 (34) 0.002
Complications
VT/VF 5 (4) 20 (9) 0.11
PAF 6 (5) 24 (10) 0.07
CHF 10 (8) 26 (11) 0.35
Recurrent MI/ischemia 31 (25) 14 (6) , 0.0001
Mortality
30-day 2/124 (1.6) 23/232 (9.9) 0.004
1-year 14/124 (11.3) 50/232 (21.6) 0.02
3-year cumulative 21/124 (16.9) 73/232 (31.5) 0.003
30-day to 3-year 19/122 (15.6) 50/209 (23.9) 0.07
*Angiography, angioplasty or CABG, not including primary angioplasty. Abbreviations as in Tables 1 and 3.
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rationale for excluding patients aged $75 years from early
thrombolytic trials (28). However, since ART by either
primary angioplasty or thrombolysis is more efficacious in
the elderly (1,29–31), its use should be advocated in elderly
patients with AMI as well, unless specific contraindications
are present.
The independent association between prior infarction
and the lower use of ART may be explained, by the fact that
in these patients the recognition of new infarction is more
difficult. They often present with a non–ST-elevation AMI,
and in about half of them the diagnosis of AMI is missed on
admission (15). Among patients with prior CABG as
compared with counterparts who did not undergo CABG,
the lesion that produces infarction is more likely to be
situated in a distal or branch vessel, and as a consequence
infarct size determined by enzymatic assessment and ECG
changes tends to be smaller, and may culminate in a
NQWMI or even be obscured (32).
Women were treated with ART less frequently than men
(39% vs. 48%, p 5 0.008). This seemingly lower use of
ART in women is related to their older age, other comorbid
conditions and longer time interval from symptom onset to
therapy, since after adjustment for age and other confound-
ing variables this difference was of borderline statistical
significance (OR 0.77, p 5 0.11). Similar findings were
noted in our earlier national AMI survey in 1992 (33), and
in other studies (34,35), whereas in other studies the use of
thrombolysis in women remained lower than in men even
after adjustment (8,18,26,36).
Killip class $II on admission was not associated with the
use of ART in this survey. In hemodynamically compro-
mised patients, those with Killip class III on admission or
with cardiogenic shock, emergent mechanical reperfusion by
either angioplasty or CABG may be a more promising
mode of reperfusion than thrombolysis (37). However, their
use in our survey was low, and they were not exclusively
performed in patients with shock. Among the 20 patients
who underwent primary angioplasty, only one patient was in
Killip class III on admission and two patients were in class
IV. Two of these three patients (one in class III and one in
class IV) died during the index hospitalization.
Determinants of the use of coronary angiography, angio-
plasty and CABG after acute reperfusion. After ART,
subsequent use of ICP during the index hospitalization was
relatively low (coronary angiography was performed in 28%,
angioplasty in 12% and CABG in 5% of the patients),
reflecting the “conservative strategy” of “watchful waiting”
with coronary arteriography (7). Markedly higher rates were
reported in the U.S., where more “invasive strategy” is in use
(7,20,22,38–41). Interestingly, the variables independently
associated with the use of ICP in both strategies were quite
similar, and included recurrent ischemia or reinfarction
(20,40), presence of NQWMI and anterior infarct location
(40) and hospitalization in centers with on-site catheteriza-
tion or CABG facilities (20,22,40,42). This finding indi-
cates the heterogeneity of the use of these procedures, which
in some centers were used more liberally. On the other
hand, in this survey and in other studies, advancing age
(20,40), Killip class $II on admission (20) and a history of
stroke or transient ischemic attack (40) were independently
associated with lower use of ICP. In these patients, perfor-
mance of ICP carries an increased procedural risk, even
though potentially elderly patients and patients with heart
failure may benefit more from such procedures as compared
with low risk patients. Diabetes was associated with lower
Figure 4. Three-year Kaplan-Meier cumulative survival curves for patients with non–Q-wave acute myocardial infarction who underwent
invasive coronary procedures (angiography, angioplasty or coronary artery bypass grafting, not including primary angioplasty) and those
who did not; p 5 0.002, by log-rank test.
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use of ICP in this survey but not in others (40,43). In
contrast to other studies that noted an independent high use
of ICP in patients treated with thrombolysis (7,20,44), this
difference was not noted. Also we did not observe a lower
use of ICP in women in the current survey, as well as in our
previous survey in 1992 (32), in accordance with some (45)
but discordant with others (8,20,36,46).
Mortality. In accordance with previous reports, powerful
independent predictors of early and long-term mortality
after AMI were age (8,9,12,13,20,47,48), heart failure on
admission or during the hospitalization course (8,9,12,13,
47,48) and diabetes (8,47,49). Women fared worse than
men, with higher early and long-term crude mortality rates.
However, after adjustment for pertinent variables, the odds
ratio for dying in women as compared with men was of
borderline statistical significance at 30 days (OR 1.39; p 5
0.15), but not thereafter, in accordance with other studies
(47,50).
Acute reperfusion therapy was associated with a border-
line early favorable prognosis (Fig. 2, Tables 3 and 4).
Similar findings were noted in other AMI surveys as well
(10,51) and in one randomized thrombolytic trial of strep-
tokinase (52). In the French AMI Survey (10), five-day
mortality was lower in patients reperfused by thrombolysis
or primary angioplasty than in counterpart patients (8.2%
vs. 5.6%); however, after multivariate adjustment this ben-
efit disappeared. In the MITI Registry (51) in-hospital
mortality was lower in patients treated with thrombolysis
(6.7% vs. 10.7%), a difference that was no longer evident
after age adjustment. In the ISAM study (52) 21-day
mortality was similar in streptokinase-treated patients and
in control subjects (5.2% vs. 6.5%, respectively). On the
other hand, most thrombolytic-controlled trials found early
survival benefit with thrombolytic therapy (1). This discrep-
ancy may be related to the selection bias of favoring patients
with low risk characteristics in thrombolytic randomized
trials. This view is also supported by the fact that in the
current survey the overall 30-day mortality rate of patients
treated with ART was higher (11.0%) than that reported in
placebo-controlled thrombolytic trials by the Fibrinolytic
Therapy Trialist Collaborative Study Group for thrombol-
ysed patients at 35 days (9.6%) (1). Another explanation for
this early borderline beneficial effect may be related to the
small sample size of our population, which lacked the power
to detect small differences between patients treated or not
with ART. In fact, in the current study, the relative
reduction in 30-day mortality between patients treated or
not with ART was 16% (11.0% vs. 13.1%, respectively).
This reduction was similar to that observed by the Fibrino-
lytic Therapy Trialist Collaborative Study Group of 17% in
thrombolysed versus nonthrombolysed patients (9.6% vs.
11.5%, respectively), which reached statistical significance
because of a much larger sample size (n 5 58,600). Indeed,
it is claimed that in estimating the effect of treatment, power
calculation suggests, that the thrombolysis effect in reducing
overall mortality will not be detected until the population
with AMI includes at least 20,000 patients (51).
Of interest is the fact that patients treated with ART had
an extended mortality benefit as compared with counterpart
patients that amplified after 30 days through 3 years (12.4%
vs. 21.1%, respectively; HR 0.73; Tables 3 and 4, Fig. 4).
Similar findings were recently published by the GUSTO
angiographic substudy investigators (3). Patients who
achieved normal (TIMI grade 3) flow in the infarct-related
artery and early preservation of the left ventricular function
had a significant survival advantage well beyond the 30 days
through two years (3). On the other hand, our findings are
in discordance with earlier placebo-controlled thrombolytic
trials demonstrating no extra benefit after hospital discharge
in thrombolysis-treated patients (2). This long-term survival
benefit in our study may be related to the greater reduction
of infarct size by earlier administration of thrombolytic
therapy (53), the wider use in recent years of new thera-
peutic modalities including aspirin, beta-blockers, and
angiotensin-converting enzyme inhibitors, better prevention
of reocclusion and reinfarction, and revascularization pro-
cedures in selected cases, as compared with earlier placebo-
controlled thrombolytic trials. Our data are not complete
concerning all medical and mechanical therapies over the
three-year period, but we have data concerning therapies
during the index hospitalization. Patients treated with ART
more often received aspirin, heparin and beta-blockers,
medications associated with improved outcome, and less
often received digitalis and diuretics, medications associated
with worse outcome, as is also evident in a lower rate of the
in-hospital complication of congestive heart failure. These
findings suggest a better preserved left ventricular function
in patients treated with ART, which culminated in a
long-term survival benefit.
Patients not treated with ART (mainly thrombolysis) had
a worse early and long-term outcome. However, the prog-
nosis of these patients differed according to the reason for
exclusion. Patients not treated with ART because of con-
traindication had the highest crude and adjusted early and
long-term mortality rates (Table 5, Fig. 3). A similar
finding was noted in our survey in 1992, among patients
excluded from the GUSTO protocol because of contrain-
dication (54). These patients may benefit from primary
angioplasty (55).
Patients with unqualifying ECG had small infarctions of
NQWMI type (67% of the patients), with a low early
mortality rate (OR 0.47) increasing thereafter (HR 1.50)
(Table 5), in accordance with cohorts in the prethrombo-
lytic era (56,57). No survival advantage was noted in
NQWMI patients when treated with ART (58). However,
despite their smaller infarct size, they may experience higher
rates of postinfarction ischemic events. Therefore, these
patients may benefit from ICP when performed during the
hospitalization course (59). This explains the higher (two-
fold) use of ICP in these patients as compared with
counterparts with a Q-wave AMI (35% [124/356] vs. 23%
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[147/643], p 5 0.003, Table 2). Moreover, the prognosis of
NQWMI patients treated or not with ICP differed, and the
early and 3-year crude mortality rates were lower in the
former (Table 6, Fig. 4). However, after adjustment, per-
formance of early ICP in patients with NQWMI was
associated with lower 30-day mortality (OR 0.21), but not
thereafter from 30 days to 3 years (HR 1.01). These results
are in accordance with the VANQWISH study (60) and the
TIMI IIIB (61) trial showing no benefit from an early
routine “invasive approach” after NQWMI. Nevertheless,
the early benefit of ICP indicates that when a “conservative
strategy” guided by ischemia approach is adopted, early ICP
in NQWMI patients is beneficial.
The outcome of patients excluded from ART because of
late arrival or other reasons did not differ significantly from
patients treated with ART. The former are older, and more
likely to be women (54) with other unfavorable character-
istics that may influence their outcome. In these patients the
use of ART 12 to 24 h after symptom onset is of limited
benefit (58).
In this survey the “conservative strategy” of “watchful
waiting” with coronary arteriography followed by mechan-
ical reperfusion was associated with a decrease in early
mortality (OR 0.53), but not thereafter, indicating a greater
benefit with ICP when performed early. On the other hand,
the higher use of ICP in hospitals with on-site catheteriza-
tion facilities was not translated into a better outcome, and
mortality rates in hospitals with and without such facilities
were similar, in accordance with reports from other regis-
tries (20,38,62,63) and randomized trials (39,40). These
findings may be explained by the fact that in Israel high risk
patients can be transferred within a reasonable time to a
tertiary center for coronary arteriography and revasculariza-
tion. However, rapid availability, timing of intervention and
other logistic problems should be considered. Also, we
assume that some patients, especially those who were
hospitalized in centers without on-site catheterization facil-
ities, underwent such procedures after discharge as was
noted in a more recent survey of our group (64), thus
minimizing the early advantage obtained with the use of
ICP during the index hospitalization.
Study limitations. The patients in this cohort were derived
from a prospective nationwide survey performed during a
two-month period in 1994. The decision whether to treat
patients with ART and/or ICP was left to the discretion of
the treating physician in each center, was not randomized
and thus may have been influenced by differences in pa-
tients’ baseline characteristics and physician bias, thus re-
sulting in the selection of less severely ill patients. Despite
multiple adjustment, we cannot conclude firmly that differ-
ences in prognosis in this study were due mainly to different
treatment strategies, although their impact on prognosis
seems very plausible. Despite these limitations, this study is
based on an unselected population, and provides informa-
tion on how the recommendations assessed from large
randomized trials are implemented in daily clinical practice
and their impact on early and long-term prognosis.
The present study includes data on in-hospital compli-
cations and long-term (3-year) mortality, but not morbidity
data such as recurrent infarction, hospitalization for unsta-
ble angina, heart failure and need for angioplasty or CABG
after discharge. We cannot exclude the possibility that even
though the mortality was lower in patients treated with
ART, their postdischarge morbidity may not have differed
from those who were not reperfused. It is also possible that
some patients underwent ICP after discharge, especially in
centers without such facilities, which may influence their
subsequent outcome.
Conclusions and clinical implications. This nationwide
survey in unselected AMI patients hospitalized in CCUs
demonstrates the extent of implementation in daily practice
of ART and ICP proven to be effective in clinical trials, and
their impact on short- and long-term prognosis after AMI.
Acute reperfusion therapy (mainly thrombolysis), used in
half of the patients, was associated with a trend for lower
early mortality, but with significantly decreased long-term
mortality, with a difference that amplified beyond the early
postinfarction period, with an extended mortality benefit
after 30 days through three years. The prognosis of patients
not treated with ART differed according to the reason for
exclusion, where patients with contraindication to ART
carried the worst prognosis. Since the frequency of the use
of thrombolytic therapy in this survey was quite high (44%),
and could not be increased significantly, it seems reasonable
that increase in the use of primary angioplasty, especially in
patients with a contraindication to thrombolysis, may fur-
ther reduce mortality of AMI patients. After ART, subse-
quent in-hospital use of ICP was relatively low as the result
of the “conservative strategy” of “watchful waiting” with
coronary arteriography followed by mechanical reperfusion,
which was independently associated with a favorable early
prognosis. Larger surveys and studies from different coun-
tries are needed to evaluate the outcome of patients treated
with “conservative” or “invasive” strategy after AMI.
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